Target intelligence / Profile preview

Lymphokine-activated killer T-cell-originated protein kinase (PBK)

Target
PBK
Molecular classification
Enzyme, Kinase, Serine/threonine protein kinase, Mitogen-activated protein kinase kinase family
01

Overview

Lymphokine-activated killer T-cell-originated protein kinase (PBK/TOPK) is a mitotic serine/threonine protein kinase belonging to the mitogen-activated protein kinase kinase (MAPKK) family. Under physiological conditions, its expression is highly restricted, primarily found in the testes, placenta, and activated T-lymphokine-activated killer cells. However, PBK/TOPK is aberrantly overexpressed in a wide range of human malignancies, including colorectal, breast, lung, and ovarian cancers, as well as hematological malignancies like acute myeloid leukemia (AML) and multiple myeloma. It plays a critical role in cell cycle progression, mitosis, and cytokinesis by phosphorylating downstream targets such as JNK1, p38, and histone H2AX, which promotes cell survival and proliferation while suppressing apoptosis. Consequently, PBK/TOPK has emerged as an attractive therapeutic target for oncology. Several small-molecule inhibitors, such as OTS514, OTS964, and HI-TOPK-032, have been developed to target its kinase activity. While these inhibitors have shown robust preclinical efficacy, challenges remain, including hematopoietic toxicities (such as leukocytopenia and thrombocytosis) and potential off-target activities, notably the inhibition of CDK11 by OTS964.

Other names
PDZ-binding kinaseT-LAK cell-originated protein kinaseTOPKPBKLAK-TPKT-lymphokine-activated killer cell-originated protein kinase
02

Mechanism of action

ATP-competitive inhibition of the kinase domain, preventing phosphorylation of downstream substrates (such as JNK1, p38, ERK, and histone H2AX) and thereby blocking cell cycle progression, inducing cytokinesis defects, and promoting apoptosis in cancer cells.

03

Biological functions

Cell cycleCell proliferationApoptosisSignal transductionMitosisSpermatogenesisAutophagyInflammation
04

Disease associations

CancerInflammationOther
05

Safety considerations

Hematopoietic toxicity (neutropenia, anemia, leukocytopenia)Thrombocytosis (transient increase in platelets)Off-target effects (e.g., OTS964 was found to also potently inhibit CDK11, which may drive its cytotoxicity rather than TOPK inhibition alone)Potential impact on spermatogenesis (due to high physiological expression in testes)
06

Interacting drugs

6 more in the full profile.

07

Biomarkers

TOPK expressionPBK expressionFLT3-ITD mutationFOXM1 expressionPhospho-histone H2AX (gamma-H2AX)Phospho-p38Phospho-JNK1

Beyond the preview

Go deeper on Lymphokine-activated killer T-cell-originated protein kinase (PBK).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lymphokine-activated killer T-cell-originated protein kinase (PBK).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call